Preserving the Promise
Academic Press Inc (Verlag)
978-0-12-809216-3 (ISBN)
The authors explicate the Translation Gap faced by early stage biotech companies, the result of problematic technology transfer and investment practices, and provide specific prescriptions for improving translation of important discoveries into safe and effective therapies.
In Preserving the Promise, Dessain and Fishman build on their collective experience as company founders, healthcare investor (Fishman) and physician/scientist (Dessain). The book offers a forward-looking, critical analysis of "conventional wisdom" that encumbers commercialization practices. It exposes the self-defeating habits of drug development in the Valley of Death, that waste money and extinguish innovative technologies through distorted financial incentives.
Dr. Dessain is the scientific co-founder and Chief Technology Officer of Immunome, Inc., a cancer immunotherapy company. He is currently an associate professor at Lankenau Institute for Medical Research (LIMR) in Pennsylvania and an attending physician at the Lankenau Medical Center, where he specializes in medical oncology, runs an immunology research laboratory, and teaches in the Hematology/Oncology fellowship program. He earned an undergraduate degree in biochemistry at Brown University and then M.D. and Ph.D. degrees from Yale University. He was an intern and resident at Brigham and Women’s Hospital and a Medical Oncology fellow at Dana Farber/Partners Cancer Care in Boston. He was a postdoctoral fellow at the Whitehead Institute for Biomedical Research in Cambridge, Massachusetts, working in the laboratory Dr. Robert A. Weinberg, an internationally renowned cancer researcher. He has lectured on biotechnology innovation at the Wharton School of the University of Pennsylvania, the Harvard i-lab, and the Yale School of Management. Scott Fishman has more than three decades’ experience as a strategic advisor to the medical technology and pharmaceutical industries. He founded and was CEO of Research by Design (RBD), a healthcare consultancy he grew to one of the foremost names in the medical information industry. He has counseled virtually every major pharmaceutical company, as well as a wide spectrum of biotechnology and medical device companies. He is currently President and CEO of Ethos LifeScience Advisors and Envisage, consultancies that provide market analysis and commercial guidance for healthcare entrepreneurs starting new ventures and for new product developers working within pharmaceutical, biotech, and medical device companies. Fishman is an enthusiastic angel investor who focuses on medical technologies. He previously chaired the Life Sciences screening committee for Robin Hood Ventures and sits on the Life Science Investment Review committee for Ben Franklin Technology Partners. He co-created and serves as program executive for the Commercialization Acceleration Program (CAP) at the Wharton School of the University of Pennsylvania, a consultancy focused on the development and funding of technology-based start-up companies. Fishman holds undergraduate and graduate degrees from the University of Pennsylvania and The University of Texas, teaches in the MBA program at Philadelphia University, and is an in-demand speaker at biotechnology development events around the United States, including recent engagements at Yale’s Healthcare Colloquium, Harvard’s i-lab, and the National Science Foundation.
Innovation Meets the Translation Gap
Chapter 1. Stop the Madness and Cure Something
Chapter 2. Into the Valley of Death
Chapter 3. Clinical Promise ≠ Investment Practice
Chapter 4. Velcade, a Biotech Success Story
Chapter 5. Biotechnology and the Future of Pharma
Chapter 6. Why Pharma Should Care About the Valley of Death
Chapter 7. Porter’s Five Forces and the Market for Angel Capital
Chapter 8. Out of the Frying Pan: The Fire’s Not So Great Either
Chapter 9. Getting to Australia
Translation Gap 1: Universities Don’t Make What Companies Need
Chapter 10. When Is an Experiment Ready for the Valley of Death?
Chapter 11. Unintended Consequences of Applying for a Patent
Chapter 12. What if It Doesn’t Actually Work?
Chapter 13. Building a Better Mousetrap
Translation Gap 2: Good Innovation Is Not Always a Good Investment
Chapter 14. Due Diligence and Angel Incentives
Chapter 15. What Is Value?
Chapter 16. Angels at the Crux of Invention
Chapter 17. Investment: A Nuanced Decision
Chapter 18. Ready for a Long-Term Relationship With a Science Experiment?
Chapter 19. Investing in Hockey Sticks
Chapter 20. Harps for Angels
Chapter 21. Connecting Innovation to Investment
Translation Gap 3: Technology Transfer Wastes Money and Innovation
Chapter 22. Mitigating Supplier Power
Chapter 23. Preventing Speeding by Closing the Road
Chapter 24. Breaking Old Habits
Epilogue
Chapter 25. Epilogue: Why We Do This
| Erscheinungsdatum | 28.10.2016 |
|---|---|
| Verlagsort | San Diego |
| Sprache | englisch |
| Maße | 152 x 229 mm |
| Gewicht | 450 g |
| Themenwelt | Geschichte ► Teilgebiete der Geschichte ► Technikgeschichte |
| Medizin / Pharmazie ► Medizinische Fachgebiete | |
| Recht / Steuern ► EU / Internationales Recht | |
| Recht / Steuern ► Wirtschaftsrecht ► Urheberrecht | |
| ISBN-10 | 0-12-809216-5 / 0128092165 |
| ISBN-13 | 978-0-12-809216-3 / 9780128092163 |
| Zustand | Neuware |
| Haben Sie eine Frage zum Produkt? |
aus dem Bereich
